Nanovesicles derived from coprococcus sp. bacteria, and use thereof

Abstract

The present invention relates to vesicles derived from bacteria of the genus Coprococcus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in clinical samples obtained from patients with breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation, compared with a normal individual, and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited. Therefore, it is expected that the vesicles derived from bacteria of the genus Coprococcus according to the present invention can be effectively used for a method of diagnosing breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy or atrial fibrillation, and for developing a composition for preventing, treating or alleviating gastritis, gastric cancer, colitis, colon cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation or an inflammatory disease.

What is claimed is: 
     
         1 . A method of diagnosing one or more diseases selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation, the method comprising the following steps:
 (a) extracting DNAs from extracellular vesicles isolated from samples of a normal individual and a subject;   (b) performing polymerase chain reaction (PCR) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16 S rDNA to obtain each PCR product; and   (c) determining a case in which a content of vesicles derived from bacteria of the genus  Coprococcus  is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation, through quantitative analysis of the PCR product.   
     
     
         2 . The method of  claim 1 , wherein the sample in Step (a) is blood. 
     
     
         3 . A method of treating, preventing, or alleviating one or more diseases selected from the group consisting of gastritis, gastric cancer, colitis, colon cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation and an inflammatory disease, the method comprising administering to a subject in need thereof a composition comprising an effective amount of vesicles derived from bacteria of the genus  Coprococcus.    
     
     
         4 . The method of  claim 3 , wherein the inflammatory disease is one or more selected from the group consisting of atopic dermatitis, acne, psoriasis, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, an inflammatory collagen vascular disease, glomerulonephritis, encephalitis, inflammatory enteritis, chronic obstructive pulmonary disease, sepsis, septic shock, pulmonary fibrosis, undifferentiated spondylosis, undifferentiated arthrosis, arthritis, inflammatory osteolysis, chronic inflammatory diseases caused by viral or bacterial infections, ulcerative colitis, inflammatory bowel disease, rheumatoid arthritis, reactive arthritis, osteoarthritis, scleroderma, osteoporosis, atherosclerosis, myocarditis, endocarditis, pericarditis, cystic fibrosis, Hashimoto's thyroiditis, Graves' disease, leprosy, syphilis, Lyme disease, borreliosis, neuroborreliosis, tuberculosis, sarcoidosis, lupus, lupus pernio, lupus tuberculosis, lupus nephritis, systemic lupus erythematosus, macular degeneration, uveitis, irritable bowel syndrome, Crohn's disease, Sjogren's syndrome, fibromyalgia, chronic fatigue syndrome, chronic fatigue immunodeficiency syndrome, myalgic encephalomyelitis, amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. 
     
     
         5 . The method of  claim 3 , wherein the inflammatory disease is a disease mediated by interleukin-6 (IL-6) or tumor necrosis factor-α (TNF-α). 
     
     
         6 . The method of  claim 3 , wherein the vesicles have an average diameter of 10 to 200 nm. 
     
     
         7 . The method of  claim 3 , wherein the vesicles are secreted naturally or artificially from bacteria of the genus  Coprococcus.    
     
     
         8 . The method of  claim 3 , wherein the vesicles derived from bacteria of the genus  Coprococcus  are vesicles derived from  Coprococcus comes.    
     
     
         9 . The method of  claim 3 , wherein the composition is pharmaceutical composition or food composition. 
     
     
         10 . The method of  claim 3 , wherein the composition is an inhalant composition. 
     
     
         11 .- 15 . (canceled) 
     
     
         16 . A cosmetic composition for preventing or alleviating inflammatory disease comprising vesicles derived from bacteria of the genus  Coprococcus  as an active ingredient. 
     
     
         17 . The cosmetic composition of  claim 16 , wherein the inflammatory disease is one or more selected from the group consisting of atopic dermatitis, acne, and psoriasis. 
     
     
         18 .- 21 . (canceled)